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occupational exposure of dermatology nurses to polycyclic aromatic hydrocarbons – evaluating the effectiveness 
of better skin protection. Scand J Work Environ Health 2009;35(3):212–221.
Objectives   We studied the uptake of  polycyclic aromatic hydrocarbons (PAH) in nurses who apply ointments 
containing coal tar to patients and investigated the effectiveness of  skin protection methods.
Methods   We determined gas-phase PAH on XAD-2 and particle-associated PAH on filters. We also used 
pads to determine PAH on the skin. Pyrene and benzo(a)pyrene were analyzed by gas chromatography/mass 
spectrometry and gas chromatography/tandem mass spectrometry; their respective urinary metabolites 1-
hydroxypyrene and 3-hydroxybenzo(a)pyrene were analyzed using high performance liquid chromatography 
with fluorescence detection.
Results   We ruled out the inhalation of  airborne pyrene and benzo(a)pyrene as the sources of  PAH expo-
sure. However, substantial amounts of  pyrene and benzo(a)pyrene were observed on the hands of  the nurses 
(median 33.0 and 16.4 ng/cm2, respectively). Excretion of  urinary 1-hydroxypyrene indicated an increased 
uptake of  pyrene in 8 out of  12 nurses. We asked 35 nurses to perform a treatment with gloves followed by a 
second treatment without gloves. The use of  gloves changed the excretion of  1-hydroxypyrene by -0.58 μmol 
(range -5.1–1.0 μmol), corresponding to a median reduction of  51.5% (P<0.001). Based on this finding, a new 
protocol was adopted, involving the permanent use of  vinyl gloves and Tyvek sleeves. The effectiveness of  this 
protocol was tested against pre-existing work practices and showed a 97% reduction in skin contamination with 
pyrene and benzo(a)pyrene, and a lowering in urinary excretion of  1-hydroxypyrene of  57%.
Conclusion   Protecting the skin more stringently reduced pyrene and benzo(a)pyrene contamination of  the 
hands, and lowered urinary excretion of  1-hydroxypyrene.
Key terms   coal tar; benzo[a]pyrene (BaP); pyrene (PYR); skin absorption; urinary excretion; biological 
 monitoring; gloves.
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Coal tar has been used in dermatology for many 
decades. Although evidence from controlled trials is 
scarce, dermatologists consider (short-term) coal tar 
treatment of  psoriasis and atopic dermatitis to be rela-
tively safe and efficacious (1–3). Coal tar is a complex 
mixture of  organic compounds that is not completely 
chemically characterized. It contains polycyclic aromatic 
hydrocarbons (PAH) including some human carcino-
gens (4). Coal tar is a second choice topical therapy. It 
is used to support first line treatment with dermatocor-
ticosteroids or topical calcineurin inhibitors (in case of  
eczema), and dermatocorticosteroids and/or vitamin D 
derivatives (in case of  psoriasis). Dutch dermatologists 
mainly use coal tar in the treatment of  eczema (72% 
versus 48% in Belgian Flanders), whereas in Flanders, 
coal tar is mainly prescribed for psoriasis (60% versus 
41% in The Netherlands) (5–6).
Patients treated with coal tar ointment (CTO) excrete 
mutagenic metabolites in urine (7). A component 
of  CTO, pyrene is metabolized to 1-hydroxypyrene 
(1-OHP) and has been observed in high concentrations in 
the urine of  patients treated for psoriasis (8). Pyrene and 
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1-OHP, although not mutagenic, can be used as markers 
for total poorly volatile (particulate) PAH exposure and as 
indicators for systemic exposure to mutagenic PAH (9). 
Also benzo[a]pyrene (BaP) and 3-hydroxybenzo(a)pyrene 
(3-OHBaP) have been proposed as markers for external 
and internal exposure to carcinogenic (high molecular 
weight) PAH, respectively (10).
Several studies have shown an increased risk of  skin 
and internal cancer in subjects with long-term coal tar 
exposure (8–18). An increase in cancer risk following 
long-term occupational exposure, although not estab-
lished for dermatology nurses, cannot be ruled out per 
se. Therefore, exposure to PAH in nurses applying tar 
products to patients’ skin must be limited as much as 
possible. In our hospital, we advise our nursing person-
nel to wear gloves when applying tar. However, applying 
tar with gloves is not always convenient for the patient 
and the nurses are inclined, especially in the treatment 
of  children, to ignore this advice. 
We did not know to what extent wearing gloves pro-
tects against coal tar exposure. To investigate the possible 
uptake of  PAH when administering CTO, we studied the 
exposure of  nurses involved in the topical application of  
CTO in the dermatology clinic. This paper summarizes 
our efforts to determine pyrene and BaP levels in the air 
around and on the skin of  nurses, and the excretion of  
their respective metabolites 1-hydroxypyrene (1-OHP) 
and 3-hydroxybenzo[a]pyrene (3-OHBaP) in urine as 
biomarkers of  internal exposure. This study was aimed at 
investigating a possible increased occupational uptake of  
PAH and finding out about the effectiveness of  a more 
adequate and rigorous protocol of  skin protection. 
Study population and methods
Subjects
The nurses who volunteered to participate in the study 
signed a consent form stating they confirmed to have 
received information about the objectives of  the study. 
The results of  the urine analyses were given to the 
occupational physician, along with a list of  the names 
of  the workers and the personal codes. This was so that 
the results of  the biological monitoring study could be 
added to the medical files and be available to the nurses 
on request.
The subjects were studied on the day that they 
treated one or more patients and during the following 
day(s). During the sampling process, the nurses were 
asked to refrain from consuming smoked, fried, grilled, 
or barbecued fish or meat in order to prevent the influ-
ence of  diet on the pattern of  urinary excretion of  
1-OHP and 3-OHBaP (8–9, 19–20).
Study design
Four different studies were performed. In each study, the 
nurses were observed following the administration of  
one or more treatments of  CTO per shift. A single treat-
ment normally takes 10–30 minutes. The first study (A) 
was designed to investigate the contribution of  inhalation 
and skin absorption as the two most obvious routes of  
uptake of  PAH due to occupational exposures. During a 
subsequent study (B), we followed three nurses during a 
prolonged period of  time and collected spot urine sam-
ples in order to study the relationship between work tasks 
and urinary excretion pattern of  PAH-metabolites. In a 
third study (C), we followed 35 nurses on two separate 
occasions involving CTO applications. This treatment 
was carried out on the same patient, so the amount of  
applied CTO, body parts treated, and the duration of  the 
treatment were similar. On the first occasion, protective 
gloves were used and, during the second occasion, no 
gloves were used. By comparing these two situations, we 
were able to quantify how wearing gloves can reduce the 
skin absorption of  PAH. In a fourth and last study (D), 
a new work procedure was tested for its effectiveness in 
protecting the nurses from the exposure of  hands and 
forearms by using vinyl gloves (Flexam vinyl, supplied 
by Cardinal Health, Dublin, OH, USA) combined with 
Tyvek® narrow sleeves (model PS32LA, Du Pont Per-
sonal Protection, Amsterdam, The Netherlands). The 
effectiveness of  this new work procedure was tested 
against results of  urinary excretion of  1-OHP obtained 
in study A. An overview of  the study components is 
presented in table 1. 
Questionnaires
Using a questionnaire, we collected information on 
each nurse’s occupational history and smoking habits, 
and uptake of  PAH from the diet and exposure to 
sources of  indoor and outdoor open fire, among oth-
ers. This questionnaire also contained a number of  
questions generally describing working practices. A 
second questionnaire was completed on each day of  
urine collection. This questionnaire covered diet, active 
smoking, consumption of  alcoholic beverages, use of  
medication, and some more specific questions about 
daily work practices (eg, the amount and type of  CTO 
administered to the patient, the use of  gloves and pro-
tective garments, and personal hygiene such as the time 
between CTO administration and washing of  hands). 
Treatment with coal tar ointment
Coal tar is applied either directly to lesions, in the 
case of  limited disease, or diffusely if  the lesions are 
disseminated. In the dermatology clinic, two different 
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types of  CTO are applied in various formulations. Used 
in the treatment of  chronic eczema, “dark” colored 
CTO contains 5% crude coal tar, 965 μg/g pyrene 
and 455 μg/g BaP (the ratio of  BaP to pyrene is 0.47). 
“Light” colored CTO, use to treat mild dermatitis and 
psoriasis, contains an alcoholic extract of  crude coal 
tar (10% solution liquor carbonis) with a much lower 
PAH content (3.0 μg/g pyrene and 0.13 μg/g BaP, with 
a BaP to pyrene ratio of  0.043). The nurse noted the 
type of  CTO used and determined the amount applied 
by weighing the container of  CTO before and after 
each single treatment. From the total amount of  CTO 
and the type of  CTO used, the total amount of  pyrene 
and BaP was calculated.
Air samples
Task-based measurements of  volatile and particulate PAH 
were conducted only during the treatment of  the patient 
(approximately 10–60 minutes per patient). Volatile PAH 
were collected on Amberlite XAD-2 (Sigma-Aldrich 
Chemie, Zwijndrecht, the Netherlands) placed in the 
breathing zone of  each nurse. The cartridge was con-
nected to an automated electronic personal air sampling 
pump (DuPont Alpha-1, Deha International, Huizen, 
the Netherlands) operated at a flow of  0.20 l/min. Air-
borne particle-associated PAH were monitored using a 
Teflon filter (Type TE38, Schleicher and Schüll, Dassel, 
Germany) placed in an air sampling probe for the collec-
tion of  inhalable particles (according to EN481). Air was 
drawn through this filter at a flow of  23.6 l/min using 
a medium volume air sampling pump (Environmental 
Monitoring Systems, Charleston, SC, USA).
Skin pads
Skin pads were homemade using polypropylene mem-
brane filters embedded in self-adhesive Fixomull stretch 
elastic bandage (BSN Medical, Almere, the Nether-
lands); see Jongeneelen et al (21) for a more detailed 
description. These pads were attached to the skin on 
three standardized places on the dominant hand: (i) the 
lateral side of  the index finger, (ii) the hand palm, and 
(iii) the lateral side of  the wrist. The pads were attached 
just before the start of  the treatment of  the patient with 
CTO and removed again directly upon completion of  
the treatment. The pads were wrapped in aluminium 
foil and kept at -20° C until analysis.
Collection of urine samples 
Urine was collected in 250 ml polyethylene (plastic) 
bottles with screw caps and a label registering the name 
and date of  birth of  the subject, and the date and time 
of  the sample collection. Each subject received a sheet 
with instructions for urine collection. Urine was first 
collected in a measuring beaker (500 ml) and the total 
volume of  the void was written down on a registration 
form. An aliquot of  the sample was transferred to the 
bottle and the residue was flushed away. Urine samples 
were kept in a cool and dark place, and taken to a cen-
tral storage facility at the Dermatology department. 
Three different schemes for urine collection were used. 
In study A, we collected all the urine samples on the 
same and consecutive day until 48 hours after the time 
of  CTO application. In study B, spot urine samples 
were collected between 9:00–22.00 hours (post-shift). 
In study C, a pre-shift spot sample was collected as 
the first void after awakening. To reduce the workload 
for the volunteers in this study, urine samples were 
collected between 8.00–18.00 hours following the 
application of  the CTO. In study D, we used the design 
of  study A and modified only the period of  urine col-
lection to 24 instead of  48 hours since these samples 
were not analyzed for 3-OHBaP.
Analysis from air filters and skin pads
The polypropylene filters were punched from the skin 
pads and extracted in 10 ml of  dichloromethane (high 
performance liquid chromatography grade purchased 
from Lab-Scan, Gliwice, Poland). The filters were 
vortexed for 1 minute followed by 15 minutes in an 
ultrasonic bath. The Teflon air filters and XAD-2 solid 
sorbent cartridges were extracted following the same 
procedure. After removing the filters, the extracts 
Table 1. Overview of study parameters. (AM = arithmetic mean, PAS = personal air sampling)
Study  N   Type of skin protection Treatments AM Urine collection
 Total Women Men    N Range Period Type of sample
A 12 a 9 3 PAS Pads With loose-fit polyethylene gloves  1.2 1–2 48 hours Total void
B 3 b 3 0 · · With and without loose-fit polyethylene gloves 7.0 6–8 23 days Spot sample
C 35 b 30 5 · · With and without loose-fit polyethylene gloves  1.0 ·· 10 hours Total void
D 16 a 12 4 · Pads With tight-fit vinyl gloves and Tyvek® narrow sleeves 2.4 2–4 24 hours Total void
a Three smokers.
b All non-smokers.
     Inhalation Skin 
    exposure exposure
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were evaporated under a gentle stream of  nitrogen at 
25°C. The residue was re-dissolved in toluene (Merck, 
Darmstadt, Germany) and injected on the gas chro-
matography/mass spectrometry and gas chromatogra-
phy/tandem mass spectrometry (GC/MS/MS) system 
(consisting of  a Varian Star 3400 CX GC system with 
a Chrompack CP-Sil 8 low bleed/MS column of  30 m 
and internal diameter of  0.25 mm with a film thick-
ness of  0.25 μm). Pyrene and BaP were detected on 
a Saturn 4D, ion trap MS/MS (Thermo Varian, Palo 
Alto, USA), using the following ions: (i) m/z of  202 
for pyrene and (ii) m/z 252 and 253 for BaP. The lim-
its of  detection were 5.3 and 10.0 pg for pyrene and 
BaP, respectively. This resulted in limits of  quantifica-
tion for pyrene and BaP in the gas phase of  0.5 ng/m3 
and 1.0 ng/m3, and in the particulate phase of  0.02 
ng/m3 and 0.04 ng/m3, respectively. The limits of  
quantification for the skin pads were 5 pg/pad for 
pyrene and 10 pg/pad for BaP. Pyrene (purity >99%) 
and BaP (purity 98%) were purchased from Sigma-
Aldrich (Zwijndrecht, the Netherlands). The analysis 
was calibrated using standards prepared in toluene in 
the range 5.87–938 ng/l for BaP and 1.48–237 ng/l 
for pyrene.
Analysis from coal tar ointment
After diluting CTO in tetrahydrofurane, we injected the 
sample directly into the chromatographic system with-
out pre-treatment. The analysis was performed with 
an high performance liquid chromatography method 
with a gradient dilution and with a detection by fluo-
rescence (excitation and emission wavelengths of  296 
and 405 nm, respectively, for BaP and 335 and 385 nm, 
respectively, for pyrene).
Urine analysis
Urine was analyzed for both glucuronide-conjugated 
and free 1-OHP in glucuronidase/sulfatase hydro-
lyzed samples using the method of  Jongeneelen et 
al (22) and urinary creatinine was analyzed using 
the Jaffé method. 1-OHP was analyzed on a high 
performance liquid chromatography system with a 
Lichrospher 100 RP-18 column with a particle size 
of  5 μm (Merck, Darmstad, Germany) using fluores-
cence detection with a limit of  detection of  2 μg/l 
and an interday repeatability of  12.6%, based on an 
analysis of  24 samples in duplicate within a period 
of  12 months. Only the urine samples that were col-
lected during study A were analyzed for 3-OHBaP. 
This analysis was performed according to the method 
described by Simon et al (23) with a limit of  detection 
of  0.1 ng/l, an intraday repeatability of  less than 3%, 
and an interday repeatability of  less than 6%.
Calculations and statistical analysis
The amounts of  pyrene and BaP used in each patient 
treatment were calculated from the type and registered 
amount of  CTO used. The concentration of  1-OHP in 
each urine sample was corrected by the urine creatinine 
content. Baseline excretion of  1-OHP was determined 
in the first void of  urine after awakening, following a 
period of  48 hours not working with CTO.
The total excretion of  1-OHP was calculated from 
the recorded volumes for each void and the concentra-
tion was determined in an aliquot. In the analysis, no 
distinction was made between female or male nurses or 
smokers and non-smokers. Smoking is estimated to be 
of  limited influence due to the study design (ie, compar-
ison of  urinary PAH metabolite excretion within each 
subject over time). Statistical testing was performed 
using SPSS version 14.0 (SPSS Inc, Chicago, IL, USA) 
using a paired Student’s t-test for the results of  study C. 
An unpaired Student’s t-test was used if  different nurses 
were compared before and after intervention (studies 
A and D). For comparison of  the urinary excretion of  
1-OHP in study A with the results of  study D, only 
the results of  urine samples collected during the first 
24 hours were used.
Results
Study A
The levels of  airborne pyrene and BaP were all below 
the limits of  quantification, suggesting that inhalation 
exposure of  pyrene and BaP due to the application of  
CTO is very unlikely. Therefore, inhalation of  airborne 
pyrene and BaP can be ruled out as a source of  occu-
pational exposure.
During this study, all the nurses wore loose-fitting 
polyethylene gloves during at least part of  each CTO 
treatment. Despite this good work practice, after one 
working shift substantial amounts of  pyrene and BaP 
were observed on the nurse’s hands. The distribution 
of  the contamination of  pyrene and BaP over three 
different pads on the same hand shows considerable 
inter-individual differences, indicating variations in the 
PAH content of  different CTO products used and pos-
sible differences in working methods.
Table 2 presents the results of  pyrene skin con-
tamination testing and urinary excretion of  1-OHP. 
For nurses A and K, the amount of  CTO used is the 
same as they were treating the same patient. This is 
also the case for nurses H and J. Nurses F and G were 
involved in the treatment of  two patients resulting in 
the highest amount of  administered CTO. However, 
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these two nurses did not have the highest skin con-
tamination values or the highest excretion levels of  
1-OHP in urine. 
Pyrene applied as part of  the CTO varies widely due 
to the use of  different types of  CTO with PAH con-
tents ranging over three orders of  magnitude. Similarly, 
the amount of  BaP applied ranged from 1.7–25 200 μg, 
with a median of  2758 μg (not presented). 
The highest level of  excretion of  1-OHP was found 
in nurse A. The urine samples of  this nurse were 
the only samples in which levels of  3-OHBaP were 
detected (figure 1). Considering the amount of  pyrene 
applied and the contamination of  skin pads, this is cer-
tainly not the person with the highest external exposure 
to pyrene. The slight downward trend in both 1-OHP 
and 3-OHBaP excretion patterns may be related to 
the use of  CTO in treatment of  a patient on the day 
before urine collection. Nurse A reported this exposure 
(not in line with the instructions) in the questionnaire. 
Since nurse A is also an active smoker, inhalation of  
tobacco smoke may have contributed to the excretion 
of  1-OHP and 3-OHBaP. 
The individual with the lowest urinary excretion 
of  1-OHP (nurse K) was treating the same patient as 
nurse A, and had lower levels of  contamination on 
the skin (except for contamination of  the finger of  
118 ng/cm2). It is likely that these two nurses divided 
the tasks during treatment of  the patient in such a 
way that nurse A had more direct contact with CTO 
than nurse K. 
We also investigated the contamination of  skin 
pads with BaP. The levels observed on the pads were 
(median and range): (i) wrist: 6.5 ng/cm2 (<0.01–
105.1), (ii) palm: 3.9 ng/cm2 (1.2–79.7), and (iii) finger: 
23.3 ng/cm2 (<0.01–98.0). The pyrene and BaP levels 
on the wrist and palm were highly correlated (R2=0.95 
and 0.97, respectively). The correlation between pyrene 
and BaP on the finger pad was weaker (R2=0.43) but 
still statistically significant (P<0.05).
We did not find statistically significant correla-
tions between the urinary excretion of  1-OHP and 
work characteristics such as the total amount of  CTO 
applied, the contamination of  PYR on the skin pads, 
Table 2. Amount of pyrene (PYR) used in coal tar ointment (CTO), skin contamination and excretion of 1-hydroxypyrene (1-OHP) during 
a period of 48 hours following the administration of CTO. (ND = not detected)
Person 
code
Age 
(years)
Smoking 
status
Number 
of 
treat-
ments
Total 
treat-
ment 
time 
(min-
utes)
PYR 
in CTO 
applied 
(μg)
Skin exposure to PYR Excretion of 1-OHP
Wrist 
(ng/cm2)
Palm 
(ng/cm2)
Finger 
(ng/cm2)
Mean 
(ng/cm2)
Total 
(ng)
Total 
excretion 
(nmol/
48 hours) 
Baseline 
excretion 
level a 
(μmol/mol)
Highest 
excretion 
level 
(μmol/mol)
Increase 
from 
baseline 
(μmol/mol)
A 51 Smoker 1 20 112 17.5 6.85 112 45.6 254 7.7 0.21 0.35 0.14
B 39 Non-smoker 1 60 438 0.43 9.33 15.9 8.55 51.9 3.8 0.09 0.21 0.12
C 28 Non-smoker 1 60 22 000 173 15.6 189 126 762 1.5 0.01 0.18 0.18
D 43 Non-smoker 1 20 6 230 14.6 1.46 56.0 24.0 146 3.9 0.11 0.15 0.04
E 39 Smoker 1 5 36.2 2.71 2.02 18.8 7.84 47.6 2.2 0.10 0.13 0.03
F 34 Smoker 2 90 31 500 43.9 3.12 52.1 33.0 201 4.0 0.07 0.13 0.06
G 40 Non-smoker 2 70 445 000 165 28.4 9.58 67.5 410 2.2 0.06 0.11 0.06
H 50 Non-smoker 1 20 83.8 300 202 49.0 184 1110 1.7 0.08 0.10 0.03
I 22 Non-smoker 1 30 4 970 0.19 0.32 9.4 3.30 20.0 1.7 0.19 0.10 -0.09
J 49 Non-smoker 1 20 83.8 68.0 19.1 55.2 47.4 287 2.4 0.09 0.09 -0.01
K 44 Non-smoker 1 20 112 0.25 1.6 118 40.1 67.9 1.2 0.03 0.04 0.01
L 29 Non-smoker 1 35 455 0.34 0.17 ND 0.17 1.10 1.3 0.05 0.04 -0.01
a Baseline excretion was determined in the first void of urine after awakening following a period of 48 hours not working with CTO.
Figure 1. Pattern of excretion of 1-OHP (dotted line) and 3-OHBaP 
(straight line) in a male nurse (person A) who reported smoking 11-
20 cigarettes/day and who treated one patient at 09:47 (time in hours; 
treatment started at t = 0). During the treatment, 55.8 g of dark CTO 
was applied during 20 minutes of working without gloves.
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the duration of  the treatment, or time elapsed between 
CTO application and washing hands. 
Study B
The results from the three-week follow-up study are 
presented in figure 2. Nurse 1 reported working a total 
accumulated period of  202 minutes without wearing 
gloves. Dark CTO was applied for only 22 minutes in 
total (on days 2, 3, 16, 17, and 19) while light CTO was 
used for the remaining 180 minutes (days 2, 3, 9, 12, 
16, 17, and 19). Of  the time used to apply CTO, 92% 
was spent without protection. During a shift where a 
significant amount of  time was spent working unpro-
tected (>30 minutes per shift), the urinary excretion of  
1-OHP increased (days 3 and 17). However, on other 
days with a similar duration of  working unprotected, no 
increase in urinary excretion of  1-OHP was observed 
(days 2, 9, 16, and 19). On day 12, working 10 minutes 
with unprotected hands resulted in a decrease of  the 
urinary excretion of  1-OHP. The elevated level of  
excretion in the pre-shift sample on day 19 may be the 
result of  a continued excretion of  a relatively high skin 
absorption of  pyrene on day 17.
For nurse 2, the reported duration of  working with 
unprotected hands amounted to 93 minutes (15 minutes 
of  which were spent using dark CTO and 78 minutes 
using light ointment). This nurse worked unprotected 
during 26% of  all the time engaged in CTO application. 
Urinary excretion did not appear to be influenced by 
the application of  CTO.
Nurse 3 reported the lowest total duration of  work 
spent applying CTO (45 minutes) and only light CTO 
was used during this time. This nurse worked unpro-
tected during 38% of  the time spent applying CTO. 
The urinary excretion of  1-OHP also showed hardly 
any significant rise. 
The total number of  hours spent in unprotected 
direct handling of  CTO led to higher levels of  urinary 
excretion in nurse 1 who worked most of  the time (and 
also a high percentage of  “CTO application time”) 
without gloves. However, this increase did not occur 
on all days where significant time was spent handling 
CTO. Use of  (primarily) light CTO by nurses 2 and 3 
did not result in a consistent rise in urinary excretion 
of  1-OHP. 
Study C
Since studies A and B did not show a consistent elevated 
excretion of  1-OHP following skin exposure to CTO, 
a third study was conducted to find out if  protecting 
hands with gloves would lead to a statistically significant 
lower uptake of  PAH in a large group of  nurses. Wear-
ing loose-fitting polyethylene transparent gloves (King 
Gloves, Braintree, MA, United States), 35 nurses were 
asked to treat a single patient and to repeat the treat-
ment in the same patient without the gloves. Repeating 
the topical application of  CTO is part of  the normal 
procedure in the clinical practice. 
The results of  the paired observations are presented 
in table 3. The wearing of  gloves during a single treat-
ment resulted in an average reduction of  51.5% in the 
total excretion of  1-OHP. The highest level of  1-OHP 
in a single spot urine sample decreased by 61.2%. As 
Figure 2. Duration of CTO treatment with gloves (dotted line) and 
without gloves (solid line) and excretion of 1-OHP in a post-shift 
(evening) urine sample (dashes). Results of three different nurses 
(non-smokers) are presented: nurse 1 upper panel, nurse 2 middle 
panel, and nurse 3 lower panel.
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expected, the urinary excretion of  1-OHP at baseline 
(as observed from the first voids after awakening) was 
not different when working with or without gloves. The 
change from baseline to the maximum excretion of  
1-OHP within 10 hours after CTO application was 74% 
lower when using gloves compared with working unpro-
tected, but this result was not statistically significant. 
Study D
A new work practice was introduced based on the 
use of  latex-free polyvinyl chloride gloves and 50 cm 
Tyvek® narrow sleeves with elastic on the wrist. With 
this new set of  skin protection equipment, study A was 
repeated to verify if  the reduction in uptake shown in 
study C would be feasible under more realistic exposure 
conditions. Since only six nurses were still working in 
the department, a paired analysis was performed in this 
subgroup. In addition, an unpaired statistical analysis 
was performed involving ten nurses from study A and 
12 other individuals from study D. In both subgroups, 
a substantial and statistically significant reduction of  
skin contamination of  more than 97% was observed for 
both pyrene and BaP (table 4). The total urinary excre-
tion of  1-OHP was reduced by 56.9% in the paired 
analysis (P<0.05) and 57.3% in the unpaired analysis 
(P<0.05). The increase from baseline to the highest 
recorded value within 24 hours after the CTO showed 
a similar trend but no statistical significant reduction 
was observed (table 5). 
Discussion
Pyrene and BaP were not detected in the gas phase and 
particle phase. For BaP, the air concentration was appar-
ently lower that the previously reported background 
value for BaP in the particulate phase of  outdoor air in 
the Netherlands of  0.05–0.15 ng/m3 (24). For the gas 
phase, our method was less sensitive (due to the lower 
air flow used during sample collection) but it is unlikely 
Table 3. Median (range) or urinary excretion of 1-OHP in nurses working with and without gloves (study C).
CTO application Excretion of 1-OHP
 Total amount excreted Highest post-exposure level Baseline Change from baseline 
 (μmol/24 h) (μmol/mol creatinine) (μmol/mol creatinine) (μmol/mol creatinine)
 Median Range Median Range Median Range Median Range
Without gloves 1.34 0.19–5.6 0.31 0.06–0.98 0.05 0.01–0.28 0.23 0.00–0.74
With gloves 0.69 0.17–3.3 0.12 0.04–0.70 0.04 0.01–0.13 0.06 0.00–0.57
Change -0.58 -5.1–1.0 a -0.18 -0.81–0.04 0.00 -0.14–0.09 -0.16 -0.74–0.02
a P<0.001
Table 4. Contamination of skin pads before and after introduction 
of a protocol for use of gloves and sleeves (studies A and D). 
(PYR = pyrene, BaP = benzo[a]pyrene, ND = not detected)
Subgroup PAH contamination PAH contamination 
  before introduction of after introduction of 
  skin protection protocol skin protection protocol 
  (ng/pad) (ng/pad)
  Median Range Median Range
Same nurses (paired observations, N=6)
 PYR 349 146–1110 0.9 a ND–35.6
 BaP 184 60.5–394 4.6 b 0.2–31.7
Different nurses (unpaired observations, N=10–12)
 PYR 173 1.1–1110 3.7 b ND–93.5
 BaP 107 5.5–394 3.2 b 0.5–171
a P<0.001.
b P<0.005.
Table 5. Excretion of 1-hydroxypyrene (1-OHP) before and after 
introduction of a new protocol for the use of gloves and sleeves.
Subgroup Before introduction After introduction 
 of skin protection of skin protection 
 protocol protocol
 Median Range Median Range
Paired observations (N=6)
 Total urinary excretion of  
 1-OHP (nmol in 24 hours) 1.6 0.84–5.0 0.69 a 0.45–3.4
 Increase of urinary excretion  
 of 1-OHP from baseline  
 (μmol/mol creatinine) 0.05 -0.01–0.18 0.03 0.01–0.17
Unpaired observations (N=10–12)
 Total urinary excretion of  
 1-OHP (nmol in 24 hours) 1.5 0.74–5.0 0.64 b 0.15–2.8
 Increase of urinary excretion  
 of 1-OHP from baseline  
 (μmol/mol creatinine) 0.04 -0.09–0.18 0.02 -0.01–0.05
a P<0.005.
b P<0.05. 
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that BaP would be present in the gas phase when this 
substance was not observed in the particulate phase. 
In contrast, significant amounts of  pyrene and BaP 
were observed on skin pads attached to the dominant 
hand. The (calculated) amounts of  BaP and pyrene 
applied to each patient using the different types of  
CTO showed a high correlation (R2=0.97). On skin 
pads, correlations were low for the finger but higher for 
the wrist and the palm of  the hand. This suggests that 
pyrene is useful as a chemical marker of  PAH exposure 
while 1-OHP is a suitable biomarker of  internal expo-
sure to BaP in the case of  CTO applications by nurses. 
This is important in this study because we were unable 
to detect urinary excretion of  3-OHBaP in all but one 
nurse in study A.
No significant correlation was observed between 
the contamination of  pyrene on the skin pads and the 
total amount of  1-OHP excreted in urine (R2=0.11). 
This may be due to inter-individual differences in 
metabolism or skin absorption but also to the limited 
capability of  estimating total skin exposure using skin 
pads. The skin contamination with CTO was not dif-
fuse but showed some patchiness. This heterogeneity 
in skin contamination is difficult to assess when using 
skin pads.
Study B showed that working without gloves is 
associated with increased urinary excretion of  1-OHP 
in particular when using dark CTO (eg, nurse 1 in figure 
2). This pattern is less pronounced in nurses 2 and 3 
who worked fewer hours unprotected and used smaller 
amounts of  dark CTO. A limitation to this finding is 
that the urinary excretion of  1-OHP is indicated by 
only one single post-shift urine sample per day. 
In study C, working with gloves showed that the 
group median 1-OHP excretion was 0.12 and the P95 
value was 0.30 μmol/mol creatinine. When the nurses 
did not wear gloves, the median and P95 were 0.31 and 
0.83 μmol/mol creatinine, respectively. The P95 values 
of  0.76 and 0.24 μmol/mol creatinine proposed by Jon-
geneelen et al (9, 25) were used to classify respectively 
smoking and non-smoking nurses as being occupation-
ally exposed to PAH. In study C, 17 out of  35 workers 
would be classified as “occupationally exposed” when 
not wearing gloves, whereas only 2 workers would be 
classified as being exposed when wearing protective 
gloves. Therefore, wearing gloves created a situation that 
would be very close to what would be considered as “no 
occupational exposure” for the group of  35 nurses.
It is also interesting to compare the level of  
observed exposure with known sources of  non-occu-
pational “background” exposure (20, 26). The group 
median uptake of  1-OHP of  2.2 nmol in 24 hours 
as calculated from table 2 is approximately 21.6% of  
what is estimated to be taken in on a daily basis from 
the diet of  non-smokers, or only 23.9% of  the amount 
estimated for active smokers if  a complete conversion 
of  pyrene to 1-OHP is assumed (20). 
In 11 of  the 12 nurses in Study A, there was no 
detection of  3-OHBaP. In part, this may be due to the 
method of  collection and storage of  urine leading to 
loss of  3-OH-BaP glucuronide. In one nurse, 3-OHBaP 
was detected in collected urine samples. This subject 
smoked 0.5–1 pack of  cigarettes per day. The urinary 
excretion for 3-OHBaP in nurse A (figure 1) was 
somewhat higher than the level that is normally seen in 
smokers (26), but well below the biological limit value 
of  0.45 nmol/mol creatinine proposed by Lafontaine et 
al (10). The highest value at 4 hours prior to the applica-
tion of  CTO and the gradually decreasing pattern of  
values suggests an uptake of  BaP on the previous day. 
The latter was confirmed by a report from nurse A who 
acknowledged that she had treated a patient with CTO 
on that day. Moreover, excretion of  1-OHP showed 
a pattern indicating a possible work-related uptake 
of  pyrene. This is consistent with a substantial skin 
contamination as indicated by a total 254 ng of  pyrene 
on all pads. The latency time between the moment of  
application (09:47 hours) and the highest value of  uri-
nary excretion (approximately 23:32 hours), suggests a 
delay of  13:45 hours, indicating skin absorption as the 
primary route of  uptake rather than smoking (27). 
The results of  study B showed that especially the use 
of  dark CTO when wearing no gloves might contribute 
to an uptake of  PAH, as indicated by the increase of  
urinary excretion of  1-OHP from pre- to post-shift. 
These results indicated that the use of  light CTO did 
not (in most cases) lead to such an increase and contrib-
uted to the explanation of  the results observed in study 
A, which showed that an increase in uptake of  PAH is 
not observed in all subjects. Furthermore, these find-
ings suggested that the role of  skin protection should 
be further investigated.
The results of  study C were related to a task-based 
study of  exposure rather than a study of  a real life 
work shift, which may involve the treatment of  two or 
more patients during the course of  a shift. The intro-
duction of  a new protocol for skin protection resulted 
in an almost complete elimination of  skin exposure 
(<3% residual exposure for pyrene and BaP). In this 
work situation, skin absorption is considered to be the 
primary route of  uptake since both inhalation and oral 
exposure are not very plausible routes of  exposure. 
So it may be concluded that most of  the occupational 
exposure to PAH due to the use of  CTO was virtually 
eliminated. This major reduction in exposure did not 
lead to a complete reduction in the excretion of  urinary 
metabolites due to the contribution of  non-occupa-
tional sources of  exposure to PAH.  
Study C was performed because it was still uncertain 
how effective a more stringent regime of  skin protection 
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would be in terms of  reduction of  PAH uptake. It was 
of  particular interest to involve the nurses in this inter-
vention study, comparing working with and without 
gloves under more or less standardized conditions. This 
participatory study design helped to convince the nurses 
of  the added value of  protecting their skin. The result of  
this study showed a substantial reduction that was also 
statistically significant based on the findings for the entire 
group. However, it should be made clear that, when 
looking at the results on an individual level, it appears 
the effectiveness may vary substantially from person to 
person: from a 5-fold increase to a 15-fold reduction. 
In study D, we showed that a twofold reduction of  
uptake of  PAH (as indicated by excretion of  1-OHP) 
is feasible for a group of  nurses working with CTO 
on a day-to-day basis inspite of  the greater number 
of  CTO treatments in study D (arithmetic mean 2.28, 
range 2–4) than in study A (arithmetic mean 1.17, range 
1–2). It is obvious that this substantial reduction in the 
contamination of  skin pads, would lead to a decrease in 
urinary excretion of  1-OHP, but the excretion observed 
was very close to levels seen in the general population 
at baseline values (9).
The influence of  smoking on this result was evalu-
ated by reanalyzing the data after excluding the smok-
ers. The removal of  the two smokers from the paired 
observations reduced the level of  significance (the 
P-value changed from 0.007 to 0.022). The removal of  
three smokers from the unpaired observations caused 
the P-value to change from 0.037 to 0.214, suggesting 
that interference of  changes in smoking patterns on the 
excretion of  1-OHP cannot be excluded in this part of  
the analysis. 
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